These innovative molecules represent a significant leap in the therapy of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates promising efficacy in controlling blood glucose levels. https://alysharqkq110068.bcbloggers.com/38036157/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide